©2024 Stanford Medicine
ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
Not Recruiting
Trial ID: NCT01971684
Purpose
The purpose of this study is to understand physician treatment decisions in selecting
specific second line treatments in pediatric ITP and to determine the effectiveness of
different second line ITP treatments. Eligible patients are those ages 1-18 years who are
starting on a new second line treatment for ITP, defined as any treatment other than IVIG,
steroids, anti-D globulin, or aminocaproic acid. Enrolled patients remain on the study for
approximately one year.
Official Title
ICON1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia
Stanford Investigator(s)
Eligibility
Inclusion Criteria:
- Immune Thrombocytopenia or Evans Syndrome
- Ages > 12 months to <18 years
- Starting a new second line therapy as defined as any therapy except IVIG, steroids,
anti-D globulin, or aminocaproic acid
- Starting a single agent/monotherapy
Exclusion Criteria:
- Evans Syndrome with a history of or current evidence of autoimmune hemolytic anemia
- Unwillingness to be followed for 1 year
- Physician providing care is unwilling to participate
- Patient is starting multiple second line agents simultaneously
Intervention(s):
drug: Second Line ITP agents
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Michael Jeng
6507361177